Saturday, October 3, 2026

USD/CNH Is 5% Down In The Last 21 Sessions

USD/CNH Is 5% Down In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 5.79% for the last 21 sessions. At 00:15 EST on Thursday, 23 March, USD/CNH (USDCNH) is $6.83.

USD/CNH's yearly highs and lows, it's 0.053% up from its 52-week low and 0.439% down from its 52-week high.

News about

  • Eur/usd price analysis: pair revisits descending trendline at 1.0720 level before FOMC meeting. According to FXStreet on Tuesday, 21 March, "The three-day bullish rally for EUR/USD has led to a retest of the descending trendline that originates from February's high at the 1.1036 level.", "A convincing break below this point could send EUR/USD down to the multi-month low of 1.0525, the last line of support."
  • Eur/usd forex signal: bullish sentiment if it Zooms past 1.0750 - 21 March 2023. According to DailyForex on Tuesday, 21 March, "The EUR/USD exchange rate bounced back after falling to a low of 1.0522 on March 15. ", "The EUR/USD rose as the US dollar index slumped to $103 and American indices like the Dow Jones and S&P 500 indices jumped by almost 1%. "
  • Eur/usd: A 50 bps increase by the fed and/or upward revision of the dots to smother bullish argument – socgen. According to FXStreet on Tuesday, 21 March, "A smaller 25 bps rate increase or a pause by the FOMC on Wednesday and minor (upward) revision of the dot-plot should, in theory, help EUR/USD to return to the upward trajectory of January.", "A 50 bps increase by the Fed and/or significant upward revision of the dots would be a major surprise and would backfire for risk assets and smother the bullish EUR/USD argument."
  • Eur/usd climbs above 1.0700 on risk-on mood, soft US dollar. According to FXStreet on Tuesday, 21 March, "At the time of writing, the EUR/USD is trading at 1.0774 after hitting a low of 1.0703.", "The EUR/USD continued to rally to a five-week high of 1.0788 but fell shy of testing the 1.0800 mark. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com